Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APEX1 | P27695 | 1/20 | 0.49 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.48 |
| ▸ | PPARG | P37231 | 6/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.43 |
| ▸ | FBP1 | P09467 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.42 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.42 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1889761 | 0.83 | KDM4E (0.44) | TLR8PPARGTSHRFBP1KDM4E | |
| SCHEMBL27678877 | 0.77 | APEX1 (0.53) | APEX1KDM4EAGTR1AGTR2PTGDR2 | |
| SCHEMBL27678874 | 0.75 | APEX1 (0.54) | APEX1PPARGKDM4EAGTR1AGTR2 | |
| SCHEMBL3825019 | 0.75 | TLR7 (0.42) | APEX1PPARGAKR1B10TLR7 | |
| SCHEMBL5617210 | 0.73 | TLR7 (0.71) | TLR8TLR7 | |
| SCHEMBL7043121 | 0.73 | AGTR1 (0.49) | APEX1PPARGAKR1B10KDM4EAGTR1 | |
| SCHEMBL1889687 | 0.72 | PTGDR2 (0.39) | APEX1PPARGTSHRAKR1B10PTGDR2 | |
| SCHEMBL1889690 | 0.71 | PPARG (0.42) | APEX1PPARGAGTR1AGTR2PTGDR2 | |
| SCHEMBL9422759 | 0.70 | APEX1 (0.84) | APEX1TSHRKDM4EAGTR1AGTR2 | |
| SCHEMBL27697873 | 0.70 | APEX1 (0.51) | APEX1KDM4EPTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110105573-A1 | BENZIMIDAZOLE ACETIC ACIDS EXHIBITING CRTH2 RECEPTOR ANTAGONISM AND USES THEREOF | WYETH | 2011-05-05 | — | — | US | disclosed |
| US-7732618-B2 | Benzimidazole acetic acids exhibiting CRTH2 receptor antagonism and uses thereof | WYETH (US) | 2010-06-08 | — | — | US | disclosed |
| US-20060106081-A1 | Benzimidazole acetic acids exhibiting CRTH2 receptor antagonism and uses thereof | WYETH | 2006-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060106081-A1 | Benzimidazole acetic acids exhibiting CRTH2 receptor antagonism and uses thereof | HRH2, TBXA2R, PTGDR2 | APEX1 4106/4885TLR8 1554/4885PPARG 123/4885 |
| US-20110105573-A1 | BENZIMIDAZOLE ACETIC ACIDS EXHIBITING CRTH2 RECEPTOR ANTAGONISM AND USES THEREOF | HRH2, TBXA2R, PTGDR2 | APEX1 4106/4885TLR8 1554/4885PPARG 123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.